IE 11 is a very old Browser and it`s not supported on this site

8. Segment reporting

(in CHF 1 000)

The sole operating segment of the Group reflects the internal management structure and is evaluated on an overall basis. Revenue is derived by investing in a portfolio of companies active in the biotechnology industry for the purpose of capital appreciation. The following results correspond to the sole operating segment of investing in companies active in the biotechnology industry.

The geographical analysis of the profit/(loss) before tax is as follows – all income from financial assets are attributed to a country based on the domiciliation of the issuer of the instrument.

Profit/(loss) before tax

 

01.01.–30.06.2021

 

01.01.–30.06.2020

USA

 

349 943

 

352 714

Netherlands

 

19 788

 

55 094

Switzerland

 

17 891

 

6 769

Canada

 

6 816

 

Singapore

 

(2 098)

 

5 496

Great Britain

 

(15 689)

 

22 269

Curaçao

 

(27 118)

 

(20 602)

 

 

349 533

 

421 740

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer